Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Mastering the Use of IL-23 Inhibitors in Psoriasis and Psoriatic Arthritis
Description
The presentation discusses the use of IL-23 inhibitors in treating psoriasis and psoriatic arthritis, emphasizing their efficacy and safety. The speaker highlights that IL-23 is a crucial cytokine for maintaining psoriatic diseases, and blocking it results in prolonged remissions. Various FDA-approved IL-23 biologics, such as guselkumab and risankizumab, show significantly high efficacy compared to other treatments, especially over a longer duration of use. Importantly, while IL-23 inhibitors may not provide rapid clearance as seen with IL-17 inhibitors, they offer longer-term disease control and better treatment persistence. Safety concerns, especially regarding cardiovascular events, warrant attention as observed in certain studies. Additionally, the speaker shares practical clinical experiences, including treatment strategies for complex cases and the importance of monitoring joint health in patients on IL-23 therapy. The session also addresses dosing strategies and the potential of higher doses to improve patient outcomes, ultimately concluding that IL-23 inhibitors are among the most effective treatments for psoriasis, with few contraindications. Further research is encouraged to explore the cardiovascular safety profile of these medications.
View moreConclusions
- IL-23 inhibitors demonstrate high efficacy in treating psoriasis and prolong remission by reducing memory T cells.
- While IL-23 inhibitors show rapid initial efficacy, IL-17 inhibitors exhibit faster action in the short term.
- IL-23 inhibitors may have a longer duration of effect compared to other biologics, benefiting patient adherence to treatment.
- Patients on IL-23 inhibitors generally face fewer contraindications and have minimal risk of reactivating latent infections.
- Real-world studies indicate that IL-23 inhibitors are associated with high treatment persistence and favorable safety profiles.
- Higher dosing regimens for IL-23 inhibitors may lead to better treatment outcomes, suggesting that current dosing might be suboptimal.
- Ongoing cardiovascular assessment is necessary for patients on IL-23 inhibitors due to observed risks in certain studies.
- Patients with psoriasis should be monitored closely for potential joint symptoms while on IL-23 inhibitors, as they can develop psoriatic arthritis.
- Lowes MA et al. Annu Rev Immunol. 2014;32:227-255.
- Lande R et al. Nat Commun. 2014;3(5):5621.
- Arakawa A et al. JEM. 2015;212(13):2203.
- Whitley SK, Li M, et al. Sci Immunol. 2022 Nov 18;7(77):eabq3254.
- Saurat JH et al. Br J Dermatol. 2008;158:558-566.
- Blauvelt A et al. J Am Acad Dermatol. 2017;76:405-417.
- Reich K et al. Lancet. 2017;390:276-288.
- Farahnik B et al. Dermatol Ther (Heidelb). 2016;6:111-124.
- Woolacott N et al. Health Technol Assess. 2006;10:1-233.
- Menter A et al. J Am Acad Dermatol. 2008;58:106-115.
- Reich K et al. Lancet. 2021;397:487-498.
- Gordon KB et al. Lancet. 2018;392:650-661.
- Langley RG et al. N Engl J Med. 2014;371:326-338.
- Griffiths CE et al. Lancet. 2015;386:541-551.
- Lebwohl M et al. N Engl J Med. 2015;373:1318-1328.
- Papp KA et al. Br J Dermatol. 2016;175:273-286.
- Thaçi D et al. J Am Acad Dermatol. 2015;73:400-409.
- Sbidian E et al. Cochrane Database Syst Rev. 2022;2022:CD011535.
- Suruki RY et al. Rheumatology (Oxford). 2022;61(8):e236-e237.
- Gelfand JM et al. Circ Cardiovasc Imaging. 2018 Jun;11(6):e007394.
- Gelfand JM et al. J Invest Dermatol. 2020 Jan;140(1):85-93.
- Daniele SG et al. bioRxiv [Preprint]. 2023 Mar 9:2023.03.09.531913.
- Masson Regnault M et al. Am J Clin Dermatol. 2022 Jul;23(4):433-447.
- Meer E et al. Ann Rheum Dis. 2022 Jan;81(1):80-86.